MX2017011732A - Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos. - Google Patents

Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.

Info

Publication number
MX2017011732A
MX2017011732A MX2017011732A MX2017011732A MX2017011732A MX 2017011732 A MX2017011732 A MX 2017011732A MX 2017011732 A MX2017011732 A MX 2017011732A MX 2017011732 A MX2017011732 A MX 2017011732A MX 2017011732 A MX2017011732 A MX 2017011732A
Authority
MX
Mexico
Prior art keywords
fusion proteins
modified alpha
alpha virus
tumor
methods
Prior art date
Application number
MX2017011732A
Other languages
English (en)
Inventor
Babad Jeffrey
Martina Pola Elin
Leonardi Peter
Original Assignee
Omnicyte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omnicyte filed Critical Omnicyte
Publication of MX2017011732A publication Critical patent/MX2017011732A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a proteínas de fusión que comprenden una o más glicoproteínas de la superficie del virus alfa modificado y uno o más antígenos específicos del tumor. También se describen proteínas de fusión que comprenden una o más glicoproteínas de la superficie del virus alfa modificado y uno o más antígenos virales específicos. También se describen proteínas de fusión que comprenden una o más glicoproteínas de la superficie del virus alfa modificado. También se refiere a métodos para activar el sistema inmune en pacientes con cáncer para infiltrar y eliminar células tumorales o células infectadas con un virus latente. La presente descripción proporciona una tecnología de plataforma que estimula una respuesta inmune más rápida, más amplia y más fuerte usando las proteínas de fusión.
MX2017011732A 2015-03-18 2016-03-18 Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos. MX2017011732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134933P 2015-03-18 2015-03-18
PCT/US2016/023203 WO2016149643A2 (en) 2015-03-18 2016-03-18 Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof

Publications (1)

Publication Number Publication Date
MX2017011732A true MX2017011732A (es) 2018-08-15

Family

ID=56919485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011732A MX2017011732A (es) 2015-03-18 2016-03-18 Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.

Country Status (12)

Country Link
US (3) US10660948B2 (es)
EP (1) EP3270958A4 (es)
JP (1) JP6921053B2 (es)
KR (1) KR20170121301A (es)
CN (2) CN114262380A (es)
AU (2) AU2016232771B2 (es)
BR (1) BR112017019776B1 (es)
CA (1) CA2979697A1 (es)
HK (1) HK1248610A1 (es)
MX (1) MX2017011732A (es)
RU (1) RU2017132190A (es)
WO (1) WO2016149643A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6921053B2 (ja) * 2015-03-18 2021-08-18 オムニサイト 改変アルファウイルス表面糖タンパク質と腫瘍関連抗原とを含む融合タンパク質、およびその手法
WO2018161092A1 (en) * 2017-03-03 2018-09-07 New York University Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
WO2019173223A1 (en) 2018-03-05 2019-09-12 New York University Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins
CN110856724B (zh) * 2018-08-24 2022-05-27 杭州康万达医药科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用
CN113939304B (zh) 2019-05-31 2024-02-23 广州威溶特医药科技有限公司 M1病毒变异体及其应用
WO2025106748A1 (en) * 2023-11-15 2025-05-22 Genvivo, Inc. Compositions and methods for therapeutic delivery

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) * 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
CN1067382A (zh) * 1990-09-26 1992-12-30 布里斯托尔-迈尔斯斯奎尔公司 人类乳头状瘤病毒肽的表达以及在致免疫组合物中的应用
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
KR20060111731A (ko) * 1997-08-05 2006-10-27 스트레스젠 바이오테크놀러지스 코포레이션 사람 유두종 바이러스 항원과 스트레스 단백질을 포함하는융합 단백질을 포함하는 조성물에 의해 유도된 사람 유두종바이러스 항원에 대한 면역 반응
US6168932B1 (en) * 1998-07-13 2001-01-02 Parker Hughes Institute Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CA2490384A1 (en) 2002-06-25 2003-12-31 Sekisui Chemical Co., Ltd. Expression vector, host, fused protein, process for producing fused protein and process for producing protein
WO2004022709A2 (en) * 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
CN100528230C (zh) * 2003-02-19 2009-08-19 台桂香 重组人muc1-mbp融合蛋白抗肿瘤疫苗及生产工艺
ATE517914T1 (de) * 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
CN100342017C (zh) * 2004-05-10 2007-10-10 中国医学科学院肿瘤医院肿瘤研究所 基因重组趋化抗原疫苗
CA2597921A1 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
ES2373055T3 (es) 2005-08-09 2012-01-31 Oncotherapy Science, Inc. Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
JP5137168B2 (ja) 2006-02-27 2013-02-06 独立行政法人科学技術振興機構 安定同位体標識脂肪族アミノ酸、その標的蛋白質への組み込み方法並びに蛋白質のｎｍｒ構造解析方法
ES2455544T5 (es) * 2009-07-24 2017-08-16 Immune Design Corp Vectores de lentivirus pseudotipificados con una glucoproteína de envoltura de virus sindbis
TWI555531B (zh) 2009-08-07 2016-11-01 傳斯堅公司 用以治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物
US20120263754A1 (en) * 2011-02-15 2012-10-18 Immune Design Corp. Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines
WO2012141984A1 (en) * 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US9637532B2 (en) * 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
JP6921053B2 (ja) * 2015-03-18 2021-08-18 オムニサイト 改変アルファウイルス表面糖タンパク質と腫瘍関連抗原とを含む融合タンパク質、およびその手法

Also Published As

Publication number Publication date
BR112017019776B1 (pt) 2020-07-28
CN114262380A (zh) 2022-04-01
RU2017132190A (ru) 2019-04-18
US11471518B2 (en) 2022-10-18
AU2016232771B2 (en) 2021-08-19
WO2016149643A2 (en) 2016-09-22
WO2016149643A3 (en) 2016-12-01
US10660948B2 (en) 2020-05-26
KR20170121301A (ko) 2017-11-01
BR112017019776A2 (pt) 2018-05-22
AU2021269306B2 (en) 2025-03-06
US20230181706A1 (en) 2023-06-15
CN107530410A (zh) 2018-01-02
EP3270958A2 (en) 2018-01-24
CN107530410B (zh) 2021-11-09
CA2979697A1 (en) 2016-09-22
AU2021269306A1 (en) 2021-12-09
JP6921053B2 (ja) 2021-08-18
EP3270958A4 (en) 2018-11-14
US20180243389A1 (en) 2018-08-30
HK1248610A1 (zh) 2018-10-19
AU2016232771A1 (en) 2017-10-05
JP2018509937A (ja) 2018-04-12
RU2017132190A3 (es) 2019-08-30
US12133885B2 (en) 2024-11-05
US20210077600A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
MX2017011732A (es) Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.
UY36538A (es) Anticuerpos humanos contra la glicoproteína del virus del ébola
MX2017008186A (es) Anticuerpos humanos para la hemaglutinina de influenza.
MX2021003175A (es) Vacuna contra el virus de la peste porcina africana.
CL2024001715A1 (es) Anticuerpo aislado que se une a la proteína e del virus del dengue; y uso.
CO2018007203A2 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
PE20171133A1 (es) Particulas tipo virus modificadas de cmv
UY35964A (es) Anticuerpos humanos para pd?1
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
IL261354A (en) Human cancer cells comprising recombinant polynucleotides encoding human leukocyte antigen (hla) genes compositions comprising same and uses thereof
MX2022006004A (es) Proteinas de fusion inmunomoduladoras y usos de las mismas.
MA49874A (fr) Vecteurs hvt recombinants exprimant de multiples antigènes de pathogènes aviaires, et vaccins les contenant
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
EA201691631A1 (ru) Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
UY35965A (es) Anticuerpos humanos contra pd?l1
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
MX383596B (es) Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.
MX383507B (es) Antígenos del virus de la inmunodeficiencia humana, vectores, composiciones y métodos de uso de estos.
AR104604A1 (es) ANTICUERPOS ANTI-FcRn
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
CO2017007105A2 (es) Nuevos virus de tilapia
IL281730A (en) Combinations of oncolytic vaccinia virus and immune checkpoint inhibitors for treating cancer, and pharmaceutical compositions comprising such combinations
MX2017011991A (es) Terapia virica con una combinacion de anticuerpos.
BR112018073007A2 (pt) terapia de combinação inicial:reforço